---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000154"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:23:25.898422+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kiora's KIO-301 shows vision improvement in blind RP patients in Phase I/II trial

## Summary
- Visual field increased significantly (p<0.05) at days 7 and 14; high-dose group gained 0.30 logMAR (3 lines) visual acuity.
- Functional MRI showed increased brain activity in visual cortex; mobility test improvement from 24.7% to 60.0% at day 28.
- No serious adverse events or retinal inflammation; duration of effect supports monthly IVT injection.
- Company plans sham-controlled Phase II trial in 2024; will share ABACUS results with FDA in Q4 2023.
- Patients with no light perception regained ability to perceive light; Odds Ratio 2.1-4.2 for light perception improvement.

## SEC filing metadata
- accession: 0001372514-23-000154
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000154/0001372514-23-000154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000154/kprx-20231104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000154
- JSON: https://secwatch.observer/filing/0001372514-23-000154.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.